Fmoc-(S)-3-氨基-5-己烯酸 | 270263-04-2

• 物质功能分类: 生物化工 - 氨基酸及其衍生物 - FMOC-氨基酸
• 分子结构分类: 有机化合物 - 苯类化合物 - 芴
• 中文名称: Fmoc-(S)-3-氨基-5-己烯酸
• 中文别名: FMOC-(S)-3-氨基-5-己烯酸
• 英文名称: (S)-3-((((9H-fluoren-9-yl)methoxy)carbonyl)amino)hex-5-enoic acid
• 英文别名: (3S)-3-(9H-fluoren-9-ylmethoxycarbonylamino)hex-5-enoic acid
• CAS: 270263-04-2
• 化学式: C₂₁H₂₁NO₄
• 分子量: 351.4
• InChiKey: SVCMPCVPSYAVJO-AWEZNQCLSA-N

物化性质

• 沸点：
  576.6±45.0 °C(Predicted)
• 密度：
  1.222±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  3.7
• 重原子数：
  26
• 可旋转键数：
  8
• 环数：
  3.0
• sp3杂化的碳原子比例：
  0.24
• 拓扑面积：
  75.6
• 氢给体数：
  2
• 氢受体数：
  4

安全信息

• 危险等级：
  IRRITANT
• 安全说明：
  S22,S24/25
• 危险性防范说明：
  P261,P264,P270,P271,P280,P301+P312,P302+P352,P304+P340,P330,P363,P501
• 危险性描述：
  H302,H312,H332

文献信息

• CONJUGATE-BASED ANTIFUNGAL AND ANTIBACTERIAL PRODRUGS
  申请人：Bapat Abhijit S.

  公开号：US20140364595A1

  公开（公告）日：2014-12-11

  The invention provides conjugate-based antifungal or antibacterial prodrugs formed by coupling at least one anti-fungal agent or antibacterial agent with at least one linker and/or carrier. The prodrugs are of formula: (i) (AFA) m -X-(L) n ; (ii) [(AFA) m′ -X] p -L; (iii) AFA-[X-(L) n′ ] q ; or (iv) (AFA) m″ -X, wherein: AFA is an antifungal agent or an antibacterial agent; L is a carrier; X is a linker; m ranges from 1 to 10; n ranges from 2 to 10; m′ is 1 to 10; p is 1 to 10; n′ is 1 to 10; and q is 1 to 10, provided that q′ and n are not both 1; and m″ is 1 to 10. The invention also provides nanoparticles comprising the conjugate-based prodrugs. Additionally, the invention also provides non-conjugated antifungal and antibacterial agents in the form of nanoparticles.

  该发明提供了由至少一种抗真菌剂或抗菌剂与至少一种连接剂和/或载体偶联形成的基于共轭的抗真菌或抗菌前药。这些前药的公式为：(i) (AFA) m -X-(L) n ; (ii) [(AFA) m′ -X] p -L; (iii) AFA-[X-(L) n′ ] q ; 或 (iv) (AFA) m″ -X，其中：AFA是抗真菌剂或抗菌剂；L是载体；X是连接剂；m范围从1到10；n范围从2到10；m′为1到10；p为1到10；n′为1到10；q为1到10，前提是q'和n不同时为1；m″为1到10。该发明还提供了包含基于共轭的前药的纳米粒子。此外，该发明还提供了以纳米粒子形式的非共轭抗真菌和抗菌剂。
• GRAMICIDIN A MUTANTS THAT FUNCTION AS ANTIBIOTICS WITH IMPROVED SOLUBILITY AND REDUCED TOXICITY
  申请人：Trustees of boston College

  公开号：US20150239936A1

  公开（公告）日：2015-08-27

  Described herein are antimicrobial peptides for use in pharmaceutical antibiotic compositions and methods of use thereof. These antimicrobial peptides are Gramicidin A (gA) peptide analogs that, in addition to having potent anti-microbial activity, have greatly increased solubility and significantly reduced toxicity in comparison to the wild-type Gramicidin A peptide.

  本文描述了用于制药抗生素组合物中的抗菌肽及其使用方法。这些抗菌肽是革兰氏阴性杆菌A（gA）肽类似物，除了具有强大的抗微生物活性外，与野生型革兰氏阴性杆菌A肽相比，它们具有极大的溶解性和显著降低的毒性。
• Lin28/let-7 crystal structures, purification protocols, and molecular probes suitable for screening assays and therapeutics
  申请人：PRESIDENT AND FELLOWS OF HARVARD COLLEGE

  公开号：US10000756B2

  公开（公告）日：2018-06-19

  The invention provides compositions and methods for regulating microRNA (miRNA) biogenesis. The invention also relates to compositions and methods for treating or preventing cancer in a subject in need thereof.

  本发明提供了调节微RNA（miRNA）生物发生的组合物和方法。本发明还涉及用于治疗或预防癌症的组合物和方法。
• Non-Newtonian photo-curable ink composition
  申请人：Hewlett-Packard Development Company, L.P.

  公开号：US10208220B2

  公开（公告）日：2019-02-19

  A non-Newtonian photo-curable ink composition that includes a polymerizable FMOC material in an amount ranging from about 2 wt % to about 20 wt % by total weight of the ink composition, a photo-initiator, an organic solvent and water, wherein the ink composition has a first dynamic viscosity ranging from 25 cps to 10,000 cps at a first state and a second dynamic viscosity ranging from 1 cps to 50 cps at a second state. Also described herein is a method for making such non-Newtonian photo-curable ink composition and a method for producing printed images using such non-Newtonian photo-curable ink composition.

  一种非牛顿型光固化油墨组合物，包括一种可聚合的 FMOC 材料（按油墨组合物总重量计，其用量从约 2 wt % 到约 20 wt %）、一种光引发剂、一种有机溶剂和水，其中该油墨组合物在第一状态下具有 25 cps 到 10,000 cps 的第一动态粘度，在第二状态下具有 1 cps 到 50 cps 的第二动态粘度。本文还描述了制造这种非牛顿光固化油墨组合物的方法和使用这种非牛顿光固化油墨组合物生产印刷图像的方法。
• Modified integrin polypeptides, modified integrin polypeptide dimers, and uses thereof
  申请人：THE CHILDREN'S MEDICAL CENTER CORPORATION

  公开号：US10273283B2

  公开（公告）日：2019-04-30

  Described herein are modified integrin α and/or β headpiece polypeptides, and crystallizable integrin polypeptide dimers comprising a modified integrin α and/or β headpiece polypeptide and a disulfide bond linking the two integrin headpiece polypeptide subunits. Methods for using the modified integrin α and/or β headpiece polypeptides and the integrin polypeptide dimers are also provided herein. For example, methods for characterizing integrin-ligand interaction and identifying integrin ligands are also provided herein. In some embodiments, the identified integrin ligands can be used as inhibitors of integrins.

  本文描述了修饰的整合素α和/或β头多肽，以及可结晶的整合素多肽二聚体，其包含修饰的整合素α和/或β头多肽和连接两个整合素头多肽亚基的二硫键。本文还提供了使用修饰的整合素α和/或β头多肽和整合素多肽二聚体的方法。例如，本文还提供了表征整合素-配体相互作用和鉴定整合素配体的方法。在某些实施方案中，鉴定出的整合素配体可用作整合素的抑制剂。